Figure 5From: Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trialMean incremental net monetary benefit (iNMB) with 95% confidence intervals (CIs). The location of the 95% CI lines below an INMB of zero indicates that the two treatment groups differed significantly with respect to cost-effectiveness.Back to article page